- In January 2023, the Zimbabwean government initiated a vaccination campaign against cholera in partnership with UNICEF and the World Health Organization (WHO). The campaign kicked off with the Health and Child Care Minister, Dr. Douglas Mombeshora, administering the first cholera vaccines during a ceremony held in Kuwadzana. This significant public health effort aims to curb the spread of cholera and protect vulnerable communities across the nation
- In December 2024, health authorities in the Congo, alongside international health partners, launched a vaccination campaign aimed at over 5 million residents across four provinces. This mass vaccination initiative, utilizing the oral cholera vaccine, is designed to safeguard vulnerable populations and play a vital role in preventing the spread of the disease to other at-risk areas. The campaign represents a crucial step in enhancing public health and controlling cholera outbreaks in the region
- In May 2024, Techinvention, a biotechnology firm, announced its collaboration with EUBIOLOGICS CO., LTD., a pharmaceutical company, to introduce Euvichol-Plus, an oral cholera vaccine, in India. This innovative vaccine will be packaged in a low-density polyethylene (LDPE) unidose format, enhancing its convenience and accessibility for patients. The partnership aims to improve cholera prevention efforts in India, particularly in areas vulnerable to outbreaks
- In November 2022, a South Africa-based biopharmaceutical company entered into a licensing and technology transfer agreement with the International Vaccine Institute (IVI), a non-profit organization based in South Korea. This collaboration aims to enhance the manufacturing of an oral cholera vaccine (OCV) to address the urgent global shortage of vaccines essential for cholera prevention. By leveraging this partnership, both organizations seek to strengthen vaccine availability and contribute to global public health initiatives against cholera outbreaks
Frequently Asked Questions
The market is segmented based on Segmentation, By Treatment (Medication and Vaccinations), Drugs (Tetracycline, Quinolones, and Others), Vaccine (Dukoral, Shanchol, Vaxchora, and Others), Route of Administration (Oral and Injectable), End Users (Hospitals, Homecare, Specialty Clinics, Primary Care Provider, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others) – Industry Trends and Forecast to 2032
.
The Global Cholera Treatment Market size was valued at USD 149.36 USD Million in 2024.
The Global Cholera Treatment Market is projected to grow at a CAGR of 8.1% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
